| Name | Title | Contact Details |
|---|
Validation Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The GW Medical Faculty Associates was incorporated in July 2000 as a non-profit, physician-led practice group. Formerly part of The George Washington University, we have grown to become the largest independent physician practice in the Washington DC metro region with more than 750 providers. Our physicians provide comprehensive patient care, offering one practice for the whole person with 52 medical and surgical specialties. As members of The GW School of Medicine and Health Sciences faculty, our providers are teachers and mentors for medical students, residents, and researchers preserving our rich tradition of academics, research, and healing. In addition to maintaining a close alliance with The George Washington University and The George Washington University Hospital, The MFA has active referring relationships with 12 area hospitals. Our leading healthcare presence in the DC metro region is complemented by a network of community-based practices in DC, Maryland and Virginia, including Adventist Medical Group, and Metro Immediate and Primary Care clinics which are wholly-owned subsidiaries of The MFA. Additionally, The MFA has some international programs in addition to the Dr. Cyrus and Myrtle Katzen Cancer Research Center, The GW Heart and Vascular Institute, and The GW Comprehensive Breast Care Center which are head-quartered at The MFA. The GW Medical Faculty Associates is a 501(c)3 with a mission of patient care, clinical research and teaching. Donate to The GW Medical Faculty Associates today.
Trust RCM is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sierra Family Medical Clinic is a Nevada City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.